Neoadjuvant therapy in MIBC

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2024-12-11 DOI:10.1038/s41585-024-00989-2

Isobel Leake

引用次数: 0

Abstract

Efficacious neoadjuvant therapy is an unmet need in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). Several early-phase clinical trials have investigated the use of immune checkpoint inhibitors (ICIs) in this context, with some promising results. A study in Nature Medicine set out to test whether the efficacy of ICIs could be improved in combination with other therapies.

Cretostimogene grenadenorepvec is an oncolytic immunotherapy, which also selectively expresses granulocyte–macrophage colony-stimulating factor (thought to boost cancer control). The authors conducted a phase Ib trial of intravesical cretostimogene and nivolumab (an ICI) to test the safety and efficacy of this combination.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.